Bristol-Myers all set to Buy Amylin for $5.3 Billion
Bristol-Myers Squibb Co (BMY) is planning to buy Amylin Pharmaceuticals Inc (AMLN), a biotechnology company, for nearly about 5.3 billion dollars cash price. This significant step
Login
X
- New Ventures
- Market Analysis
- Emerging Markets
- Technology
- Professional Services
- Media & Entertainment
- Manufacturing & Retail
- Logistics & Supply Chain
- Healthcare & Pharmaceutical
- Financial Services
- Energy
- Autos
- Aerospace & Defense
- Work-Life Balance
- Strategic Thinking
- Productivity
- Decision Making
- Communication
- Sustainability
- Success Story
- Power Players
- Philanthropy
- People
- Innovation
- CEO Magazine
